PE20040068A1 - Decanoato, undecanoato y dodecanoato de etonogestrel - Google Patents

Decanoato, undecanoato y dodecanoato de etonogestrel

Info

Publication number
PE20040068A1
PE20040068A1 PE2003000517A PE2003000517A PE20040068A1 PE 20040068 A1 PE20040068 A1 PE 20040068A1 PE 2003000517 A PE2003000517 A PE 2003000517A PE 2003000517 A PE2003000517 A PE 2003000517A PE 20040068 A1 PE20040068 A1 PE 20040068A1
Authority
PE
Peru
Prior art keywords
etonogestrel
dodecanoate
undecanoate
refers
progestogens
Prior art date
Application number
PE2003000517A
Other languages
English (en)
Inventor
Dirk Leysen
Der Voort Hendrikus Adrianus Antonius Van
Arij Jan Grootenhuis
Nijs Henrik De
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of PE20040068A1 publication Critical patent/PE20040068A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Abstract

SE REFIERE A NUEVOS PROGESTOGENOS DE ESTERES, TALES COMO DECANOATO DE ETONOGESTREL, UNDECANOATO DE ETONOGESTREL Y DODECANOATO DE ETONOGESTREL QUE SE APLICAN PARA LA ANTICONCEPCION, EN TERAPIA DE REEMPLAZO HORMONAL Y EN EL TRATAMIENTO O PREVENCION DE LOS DESORDENES GINECOLOGICOS. SE REFIERE TAMBIEN A UN KIT ANTICONCEPTIVO Y/O HRT QUE COMPRENDE UNA CANTIDAD ANTICONCEPTIVA Y/O TERAPEUTICAMENTE EFECTIVA DE LOS PROGESTOGENOS MENCIONADOS. SE REFIERE TAMBIEN AL USO DE LOS MISMOS PARA LA PREPARACION DE UN MEDICAMENTO PARA LA ANTICONCEPCION Y/O HRT
PE2003000517A 2002-05-30 2003-05-28 Decanoato, undecanoato y dodecanoato de etonogestrel PE20040068A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02077119 2002-05-30

Publications (1)

Publication Number Publication Date
PE20040068A1 true PE20040068A1 (es) 2004-02-18

Family

ID=29595014

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000517A PE20040068A1 (es) 2002-05-30 2003-05-28 Decanoato, undecanoato y dodecanoato de etonogestrel

Country Status (31)

Country Link
US (1) US7323454B2 (es)
EP (1) EP1513861B1 (es)
JP (1) JP4716726B2 (es)
KR (1) KR20050009723A (es)
CN (2) CN101100480A (es)
AR (1) AR040130A1 (es)
AT (1) ATE349458T1 (es)
AU (1) AU2003238081B2 (es)
BR (1) BR0311254A (es)
CA (1) CA2487722C (es)
CO (1) CO5631449A2 (es)
DE (1) DE60310714T2 (es)
DK (1) DK1513861T3 (es)
ES (1) ES2277085T3 (es)
HK (1) HK1072609A1 (es)
HR (1) HRP20041101A2 (es)
IL (1) IL165087A0 (es)
IS (1) IS2421B (es)
MX (1) MXPA04011797A (es)
NO (1) NO20044898L (es)
NZ (1) NZ536619A (es)
PE (1) PE20040068A1 (es)
PL (1) PL373855A1 (es)
PT (1) PT1513861E (es)
RS (1) RS97604A (es)
RU (1) RU2325910C2 (es)
SI (1) SI1513861T1 (es)
TW (1) TW200403065A (es)
UA (1) UA80126C2 (es)
WO (1) WO2003102012A2 (es)
ZA (1) ZA200410410B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
KR101406415B1 (ko) 2005-07-15 2014-06-19 미셀 테크놀로지즈, 인코포레이티드 제어된 형태의 약물 분말을 함유하는 중합체 코팅
AU2007243268B2 (en) 2006-04-26 2013-06-13 Micell Technologies, Inc. Coatings containing multiple drugs
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
JP5603598B2 (ja) 2007-01-08 2014-10-08 ミセル テクノロジーズ、インコーポレイテッド 生物分解層を有するステント
BRPI0910969B8 (pt) 2008-04-17 2021-06-22 Micell Technologies Inc dispositivo
JP2011528275A (ja) 2008-07-17 2011-11-17 ミセル テクノロジーズ，インク． 薬物送達医療デバイス
US20100239635A1 (en) 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
JP2012522589A (ja) 2009-04-01 2012-09-27 ミシェル テクノロジーズ，インコーポレイテッド 被覆ステント
EP3366326A1 (en) 2009-04-17 2018-08-29 Micell Technologies, Inc. Stents having controlled elution
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
EP2560576B1 (en) 2010-04-22 2018-07-18 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
WO2012009684A2 (en) 2010-07-16 2012-01-19 Micell Technologies, Inc. Drug delivery medical device
WO2013012689A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
EP2967803B1 (en) 2013-03-12 2023-12-27 Micell Technologies, Inc. Bioabsorbable biomedical implants
KR102079613B1 (ko) 2013-05-15 2020-02-20 미셀 테크놀로지즈, 인코포레이티드 생흡수성 생체의학적 임플란트
RU2595818C1 (ru) * 2015-05-25 2016-08-27 Федеральное государственное бюджетное научное учреждение "Научный центр проблем здоровья семьи и репродукции человека" Способ комплексного лечения дисфункции яичников при применении гормонального контрацептива имплантата "импланона"
CN111057120B (zh) * 2019-12-27 2021-04-27 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1013284B (de) 1956-03-22 1957-08-08 Schering Ag Verfahren zur Einfuehrung der Reste wenig reaktionsfaehiger Carbonsaeuren, insbesondere des ª‰-Cyclopentyl-propionylrestes, in die 17ª‡-staendige Oxygruppe solcher Steroide, die am Kohlenstoffatom 17 neben der Oxygruppe eine Acetylgruppe tragen
GB845442A (en) 1956-03-22 1960-08-24 Schering Ag Manufacture of steroid compounds
GB8313921D0 (en) * 1983-05-19 1983-06-22 World Health Org Contraceptive compositions
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4240806A1 (de) 1992-12-01 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPH07101884A (ja) 1993-10-01 1995-04-18 Sanei Gen F F I Inc 水溶性ヘミセルロースを含有する製剤
AU692504B2 (en) 1993-12-27 1998-06-11 Akzo Nobel N.V. Percutaneously absorbable preparation
DE19613698A1 (de) 1995-07-17 1997-01-23 Schering Ag Mittel zur transdermalen Applikation enthaltend Ester des 13-Ethyl-17ß-hydroxy-11-methylen-18,19-dinor-17alpha-pregn-4-en-20-yn-3-ons
WO1997003709A1 (de) * 1995-07-17 1997-02-06 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel
AU4513099A (en) 1998-06-19 2000-01-10 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
EP1087986B1 (en) 1998-06-19 2002-04-10 Akzo Nobel N.V. 7.alpha.-methyl 19-nortestosterone undecanoate with androgenic activity
US6180682B1 (en) 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters

Also Published As

Publication number Publication date
CA2487722A1 (en) 2003-12-11
RU2325910C2 (ru) 2008-06-10
IL165087A0 (en) 2005-12-18
WO2003102012A9 (en) 2005-01-13
MXPA04011797A (es) 2005-03-31
JP2005532350A (ja) 2005-10-27
SI1513861T1 (sl) 2007-06-30
DK1513861T3 (da) 2007-04-10
AR040130A1 (es) 2005-03-16
HRP20041101A2 (en) 2004-12-31
CO5631449A2 (es) 2006-04-28
EP1513861A2 (en) 2005-03-16
AU2003238081A1 (en) 2003-12-19
TW200403065A (en) 2004-03-01
PL373855A1 (en) 2005-09-19
CA2487722C (en) 2011-07-19
DE60310714T2 (de) 2007-10-11
AU2003238081B2 (en) 2008-09-18
WO2003102012A2 (en) 2003-12-11
ZA200410410B (en) 2006-02-22
NO20044898L (no) 2005-02-25
UA80126C2 (en) 2007-08-27
JP4716726B2 (ja) 2011-07-06
RU2004138807A (ru) 2005-05-27
IS2421B (is) 2008-10-15
ES2277085T3 (es) 2007-07-01
BR0311254A (pt) 2005-03-15
US20050222113A1 (en) 2005-10-06
ATE349458T1 (de) 2007-01-15
HK1072609A1 (en) 2005-09-02
NZ536619A (en) 2007-09-28
US7323454B2 (en) 2008-01-29
DE60310714D1 (de) 2007-02-08
EP1513861B1 (en) 2006-12-27
CN1314701C (zh) 2007-05-09
RS97604A (en) 2006-10-27
KR20050009723A (ko) 2005-01-25
CN101100480A (zh) 2008-01-09
IS7528A (is) 2004-11-15
WO2003102012A3 (en) 2004-04-22
CN1692122A (zh) 2005-11-02
PT1513861E (pt) 2007-03-30

Similar Documents

Publication Publication Date Title
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
BR0107869A (pt) Composições farmacêuticas eletrogiradas
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
AR012304A1 (es) Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
GT200600307A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
DK1089722T3 (da) Transdermalt plaster af matrixtypen til steroidhormoner
PE20070329A1 (es) Composiciones con estrogenos y metodos terapeuticos para su uso
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
GT200500003A (es) Composicion farmaceutica apta para la compresion directa para la administracion oral de cci-779
BRPI0400214A (pt) Composições e aplicações farmacêuticas para a obtenção confiável de nìveis aceitáveis de testosterona no soro
AR047191A1 (es) Metodos de tratamiento de fibrosis hepatica
BR0214634A (pt) Sistemas terapêuticos transdérmicos contendo hormÈnio esteróide e contendo monocaprilato de propilenoglicol
ES2180690T3 (es) Preparacion de composiciones que comprenden st1435 para aplicacion topica.
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
AR028986A1 (es) USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
PT1220676E (pt) Prevencao do cancro colorrectal
BRPI0519006A2 (pt) uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
AR049195A1 (es) Uso de una combinacion de etinilestradiol y acetato de clormadinona para la preparacion de un medicamento
AR043013A1 (es) Composicion farmaceutica destinada al tratamiento de la endometriosis
BR9814136A (pt) Conjunto contraceptivo, processos de fabricação do mesmo e de tratamento de sangramento, usos de anti-progestogênio, de progestogênio e de anti-progestogênio, e, de um composto.
ATE419855T1 (de) Therapie für hormonersatz und depression enthaltend dienogest

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed